Global Biologics Market Companies

Request for TOC Request for TOC Speak to Analyst Speak to Analyst Buy Now Buy Now Inquire Before Buying Inquire Before Free Sample Report Free Sample Report

Global Biologics Market Companies

  • Pharmaceutical
  • Upcoming Report
  • May 2022
  • Global
  • 350 Pages
  • No of Tables: 220
  • No of Figures: 60

Companies Covered

Highest Market Share

Dominant Companies

    Other Companies

    Market Share Analysis

    120120100100808060604040202000201620162017201720182018201920192020202020212021202220222023202320242024202520252026202620272027
    120120100100808060604040202000201620162017201720182018201920192020202020212021202220222023202320242024202520252026202620272027
    120120100100808060604040202000201620162017201720182018201920192020202020212021202220222023202320242024202520252026202620272027
    120120100100808060604040202000201620162017201720182018201920192020202020212021202220222023202320242024202520252026202620272027
    120120100100808060604040202000201620162017201720182018201920192020202020212021202220222023202320242024202520252026202620272027

    Star The data presented is for visualization purposes only and may not reflect actual results.

    No data available.

    Nucleus : Company Analysis Platform

    Frequently Asked Questions

    The market is segmented based on , By Type (Tumor Necrosis Factor (TNF) Inhibitor, T-cell Inhibitor, Selective Co-stimulation Modulators, Interleukin-6 (IL-6) or Interleukin-17 Blocker, Interleukin-1 (IL-1) Blocker, B-cell Inhibitor), Drug Class (Monoclonal Antibody, Recombinant Insulin, Vaccine, Blood Factor, Human Growth Hormone, Erythropoietin, Fusion Protein, Recombinant Enzyme, Interferon, Colony-stimulating Factor, Gene Therapy, Cell Therapy, Oligonucleotides, Others), Therapeutic Application (Oncology, Autoimmune/Immunologic Diseases, Metabolic Disorders, Ophthalmic Diseases, Respiratory Disorders, Inflammatory Bowel Diseases (IBDs), Neurological Disorders, Cardiovascular Diseases (CVDs), Musculoskeletal Disorders (MSDs), Infectious Diseases, Others), Source (Microbial, Mammalian, Others), Manufacturing (Outsourced, In-House), Drug Type (Branded Drugs, Generic Drugs), Mode of Purchase (Prescription Drugs, Over-The-Counter (OTC) Drugs), Dosage Form (Injection, Tablets, Others), Route of Administration (Oral, Parenteral, Others), End-Users (Hospitals, Specialty Clinics, Homecare, Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Others) – Industry Trends and Forecast to 2029 .
    The Global Biologics Market size was valued at USD 264.00 USD Billion in 2021.
    The Global Biologics Market is projected to grow at a CAGR of 9.25% during the forecast period of 2022 to 2029.
    The major players operating in the market include Pfizer , GlaxoSmithKline plc, Novartis AG, Mylan N.V., Teva Pharmaceutical Industries , Sanofi, Boehringer Ingelheim International GmbH., AstraZeneca, Johnson & Johnson Private Limited, Merck & Co. , F. HoffmannLa Roche , BristolMyers Squibb Company, Eli Lilly and Company, Allergan, Abbott, LEO Pharma A/S, Sun Pharmaceutical Industries , Aurobindo Pharma, Lupin, Hikma Pharmaceuticals PLC, Zydus Cadila.
    The market report covers data from the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.